NewAmsterdam Pharma (Nasdaq: NAMS) reported that its Board Compensation Committee granted inducement equity awards under the company’s 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). Three non-executive new hires received share options covering an aggregate of 28,000 ordinary shares with an exercise price of $27.79, equal to the July 31, 2026 Nasdaq closing price. These options vest over four years, with 25% after one year and the remainder in 36 monthly installments, subject to continued service.
The committee also granted 8,200 restricted stock units (RSUs) in aggregate to the same group, effective August 1, 2026. The RSUs vest over three years in equal annual installments, also contingent on continued employment and governed by the 2024 Inducement Plan and related award agreements.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Explained
The grants create a conditional path for the $28,000 option shares and $8,200 RSU shares to reach the three new hires, so any ownership effect for existing holders is prospective rather than an immediate reported issuance.
Market Context
The July 2 inducement-grants precedent carried a 0.2% 24-hour reaction, while the platform recorded ...
Analysis
The July 2 inducement-grants precedent carried a 0.2% 24-hour reaction, while the platform recorded Net Selling insider sentiment over 90 days. Those references frame the awards alongside vesting conditions and equity-compensation considerations.
Key Figures
Share options:28,000 ordinary sharesNew hires:3Exercise price:$27.79 per share+5 more
8 metrics
Share options28,000 ordinary sharesInducement grants to three non-executive new hires
New hires3Recipients of share options
Exercise price$27.79 per shareShare options granted August 1, 2026
Option vesting4 yearsShare options
Initial vesting25%Share options vesting on the one-year anniversary
Restricted stock units8,200 ordinary sharesInducement grants to three non-executive new hires
RSU vesting3 yearsRestricted stock units
Annual RSU vestingOne-thirdVesting on each of the one-year, two-year, and three-year anniversaries
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
The platform history showed mixed reactions, including a negative response to a positive CHMP opinion and a positive response to prior inducement grants.
"approved the grant of inducement share options covering an aggregate"
Inducement share options are stock options granted to a new hire as a special incentive to join a company, issued outside the company’s standard employee share plans. For investors, they matter because they create potential future dilution of existing shares and represent a cash‑free form of compensation that signals how much the company values attracting particular talent—like offering a signing bonus paid in future ownership rather than cash.
restricted stock unitsfinancial
"approved the grant of restricted stock units covering an aggregate"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
ldl-cmedical
"patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol"
LDL-C stands for low-density lipoprotein cholesterol, the portion of cholesterol carried in the blood by LDL particles that is commonly linked to buildup of plaque in arteries—think of it like sticky debris that can clog pipes. Investors care because changes in LDL-C are a key measure used by regulators and clinicians to judge the effectiveness of cardiovascular drugs and devices, shape insurance coverage, and influence market demand for treatments that lower heart attack and stroke risk.
cetp inhibitormedical
"obicetrapib, an oral, low-dose and once-daily CETP inhibitor"
A CETP inhibitor is a medicine that blocks a blood protein responsible for moving cholesterol between different carriers, which typically raises “good” HDL cholesterol and can lower “bad” LDL cholesterol. For investors, these drugs matter because if clinical trials and regulators confirm they reduce heart disease, they can create large new revenue streams for developers; conversely, trial failures or safety concerns can sharply reduce a company’s value, like a promising new tool that must still prove it fixes the problem.
NAARDEN, The Netherlands and MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 28,000 of NewAmsterdam’s ordinary shares to three non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price per share equal to $27.79, which represents the closing market price on the Nasdaq Stock Market of the Company’s ordinary shares on July 31, 2026, the last trading day preceding August 1, 2026, the grant date.The shares subject to the options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 equal monthly installments thereafter, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The options are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement covering the grant.
The Compensation Committee of NewAmsterdam’s Board of Directors also approved the grant of restricted stock units covering an aggregate of 8,200 of NewAmsterdam’s ordinary shares to three non-executive new hires. The restricted stock units were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the 2024 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units were granted on August 1, 2026. The restricted stock units will vest over three years, with one-third of the restricted stock units vesting on each of the one-year, two-year and three-year anniversaries of the applicable vesting commencement date, subject to each employee’s continued service with NewAmsterdam on such vesting dates. The restricted stock units are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of a restricted stock unit award agreement covering the grant.
About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
What inducement equity awards did NewAmsterdam Pharma (NAMS) grant on August 1, 2026?
NewAmsterdam Pharma granted share options on 28,000 ordinary shares and 8,200 restricted stock units to three non-executive new hires. According to NewAmsterdam, these inducement awards were issued under the 2024 Inducement Plan in line with Nasdaq Listing Rule 5635(c)(4).
What is the exercise price and vesting schedule of NewAmsterdam Pharma’s new inducement stock options?
The inducement stock options have a per-share exercise price of $27.79 and vest over four years. According to NewAmsterdam, 25% vests on the one-year anniversary, with the remaining 75% vesting in 36 equal monthly installments, subject to continued service.
How do the restricted stock units granted by NewAmsterdam Pharma (NAMS) vest for new hires?
NewAmsterdam’s inducement restricted stock units vest over three years in three equal annual installments. According to NewAmsterdam, one-third vests on each of the one-year, two-year, and three-year anniversaries of the vesting commencement date, contingent on continued employment.
Why did NewAmsterdam Pharma use Nasdaq Listing Rule 5635(c)(4) for these NAMS equity grants?
NewAmsterdam used Nasdaq Listing Rule 5635(c)(4) to grant equity awards as a material inducement for employment. According to NewAmsterdam, the options and RSUs were approved by the Board’s Compensation Committee under the 2024 Inducement Plan for three non-executive new hires.
How many NewAmsterdam Pharma ordinary shares are covered by the latest inducement grants?
The latest inducement grants cover 28,000 ordinary shares through stock options and 8,200 ordinary shares through restricted stock units. According to NewAmsterdam, all awards are issued under the 2024 Inducement Plan and are subject to standard plan and award agreement terms.
